Health Care & Life Sciences » Biotechnology | BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
 -
Market Cap
 -
Shares Outstanding
 109.38 M
Public Float
 83.54 M
BioCryst Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
 $1
Market Cap
 $411.47 M
Shares Outstanding
 110.31 M
Public Float
 108.28 M

Profile

Address
4505 Emperor Boulevard
Durham North Carolina 27703
United States
Employees -
Website http://www.biocryst.com
Updated 07/08/2019
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430.

Financials

View All
Created with Highcharts 5.0.14BioCryst Pharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.30 10830 10845 18945 18943 01943 01955 14455 14465 78265 782101 252101 252201320142015201620172018025k50k75k100k125k
Created with Highcharts 5.0.14BioCryst Pharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.17 33117 33113 60813 60848 25748 25726 35326 35325 18625 18620 65320 653201320142015201620172018010k20k30k40k50k60k

Robert Alexander Ingram
Chairman
Jon P. Stonehouse
President, Chief Executive Officer & Director
View All

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.